Drug Resistance, Bacterial
10
2
2
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
10%
1 trials in Phase 3/4
0%
0 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (10)
Effect of Oral Microbiota on MDRO Decolonization
Optimising Community Antibiotic Use and Infection Control With Behavioural Interventions in Burkina Faso and DR Congo
Prevalence of Carriage of Extended-Spectrum Beta-Lactamase (ESBL)-Producing Enterobacteria in Preterm Premature Rupture of Membranes : A French Multicenter Cohort Study
Comparison of Three Interventions for Antibiotic-Resistant Bacteria (ARB) Decolonization From the Gastrointestinal Tract
Antibiotic Treatment for Pneumonia Caused by Stenotrophomonas Maltophilia in ICU Patients
Staphylococcus Haemolyticus in the Neonatal Intensive Care Unit of CHSD in 2023: Analysis and Trends
Piperacillin/Tazobactam Versus Carbapenems in Non-bacteremic UTI Due to -ESBL-producing Enterobacteriaceae
Fecal Microbiota Transplantation (FMT) to Decolonize Antibiotic - Resistant Bacteria (ARB) - New Protocol
Prevalence of ESBL-producing Enterobacteriaceae as Carbapenem-resistant Enterobacteriaceae in Nursing Homes.
Local Collagen-Gentamicin and Extra Fixation of the Sternum for Prevention of Sternal Wound Infection in Cardiac Surgery